Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol

BACKGROUND: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. Hist...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Med Oncol
Hauptverfasser: Avallone, Antonio, Piccirillo, Maria Carmela, Di Gennaro, Elena, Romano, Carmela, Calabrese, Filomena, Roca, Maria Serena, Tatangelo, Fabiana, Granata, Vincenza, Cassata, Antonio, Cavalcanti, Ernesta, Maurea, Nicola, Maiolino, Piera, Silvestro, Lucrezia, De Stefano, Alfonso, Giuliani, Francesco, Rosati, Gerardo, Tamburini, Emiliano, Aprea, Pasquale, Vicario, Valeria, Nappi, Anna, Vitagliano, Carlo, Casaretti, Rossana, Leone, Alessandra, Petrillo, Antonella, Botti, Gerardo, Delrio, Paolo, Izzo, Francesco, Perrone, Francesco, Budillon, Alfredo
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2020
Schlagworte:
Study Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425244/
https://ncbi.nlm.nih.gov/pubmed/32849914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920929589
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge